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Pyridoxamine improves functional, structural, and biochemical
alterations of peritoneal membranes in uremic peritoneal dial-
ysis rats.
Background. We previously suggested that biochemical al-
terations of peritoneal membrane associated with long-term
peritoneal dialysis might be, at least in part, accounted for by
reactive carbonyl compounds overload originating both from
uremic circulation and heat sterilization of glucose peritoneal
dialysis fluid. In the present study, we utilized a uremic rat model
on peritoneal dialysis and evaluated the protective effects of
pyridoxamine, a recently developed inhibitor of advanced gly-
cation end product (AGE), on structural, functional, and bio-
chemical alterations of peritoneal membrane.
Methods. Uremic rats were generated by subtotal nephrec-
tomy, some of which were undergone peritoneal dialysis with
dialysate and/or given intraperitoneal pyridoxamine. Func-
tional [dialysate/plasma ratio (D/P)urea,creatinine, D/D0 glucose],
structural (density of blood vessels in peritoneal membrane
tissues), and molecular biochemical [formation of pentosi-
dine, an AGE, by high-performance liquid chromatography
(HPLC) assay and expressions of vascular endothelial growth
factor (VEGF), and fibroblast growth factor 2 (FGF-2), by
semiquantitative polymerase chain reaction (PCR) and/or im-
munohistochemistry] alterations of peritoneal membrane were
assessed.
Results. Uremic peritoneal membrane was characterized by
an increased functional area of exchange for small solutes be-
tween blood and dialysate, vascular proliferation, increased
AGE genesis, and up-regulated expressions of angiogenic cy-
tokines. The peritoneal membrane alterations associated with
peritoneal dialysis are similar but more severe than those in ure-
mia without peritoneal dialysis. Pyridoxamine given in uremic
rats with peritoneal dialysis significantly improved functional
and structural alterations. This improvement was accompanied
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by reduction of AGE accumulation and of angiogenic cytokines
expressions.
Conclusion. Peritoneal carbonyl stress derived from uremia
as well as peritoneal dialysis procedure might contribute to the
vascular proliferation through induction of bioactive molecules
and to an increased functional area, eventually leading to ultra-
filtration failure. Pyridoxamine may be beneficial in protection
of uremic peritoneal membrane on peritoneal dialysis.
Patients undergoing long-term peritoneal dialysis suf-
fer from a progressive deterioration of the peritoneal
membrane function, and this condition is characterized
by the enhanced dissipation of the glucose-dependent os-
motic gradient across the peritoneal membrane and the
loss of ultrafiltration capacity [1, 2]. The changes in the
functional characteristics of the failing peritoneal mem-
brane are best described as an increased functional area
of exchange for small solutes (urea, creatinine, and glu-
cose) between the blood and the dialysate, which is de-
scribed as effective peritoneal surface area (EPSA) [3].
These patients rely on enhanced angiogenesis and, pos-
sibly, vasodilation of the peritoneal vessels [4].
The molecular mechanisms underlying the peritoneal
membrane failure remain elusive. Although recurrent
episodes of peritonitis with associated inflammatory
changes damage the peritoneal membrane over time
[1, 5], this is not a predisposing condition for the develop-
ment of ultrafiltration failure [4, 6]. Recent studies have
provided an insight into the putative mechanisms of peri-
toneal membrane deterioration in long-term peritoneal
dialysis patients [8–14]. Chronic uremia by itself modi-
fies the peritoneal membrane and increases the EPSA
[8]. Biochemical alterations in the peritoneum might be,
at least in part, a result of the severe reactive carbonyl
compounds (RCOs) overload originating both from
the uremic circulation and the peritoneal dialysis fluid
(“peritoneal carbonyl stress”) [9–14]. The plasma RCOs
accumulate in the uremic circulation and diffuse slowly
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Fig. 1. Protocol for animal experiments. Six-
week-old rats were assigned to uremic sham-
operated groups. Five weeks after subto-
tal nephrectomy, indwelling intraperitoneal
catheters and subcutaneous access ports were
surgically implanted in the rats. Peritoneal
dialysis (PD) was continued until 21 weeks
after birth.
into the peritoneal cavity. They initiate the modification
of advanced glycation end product (AGE) [15–21]. Dur-
ing peritoneal dialysis, the RCOs produced due to the
heat-sterilization of glucose peritoneal dialysis fluid en-
ter the peritoneum. These are complemented by an in-
creased mass transfer of serum RCOs during the dialysis
procedure. The peritoneal carbonyl stress accelerates the
irreversible structural modification of peritoneal mem-
brane proteins by AGE. The peritoneal membrane pro-
tein might further stimulate cytokine and growth factor
[including vascular endothelial growth factor (VEGF)]
production and regulate nitric oxide synthase (NOS) ex-
pression in peritoneal cells [22–25]. The combination of
VEGF and nitric oxide stimulates angiogenesis, increases
permeability, and vasodilates peritoneal capillaries [23–
25]. These combined modifications may increase EPSA,
which results in the dissipation of the osmotic gradient
at a rate that is faster than normal and result in an even-
tual loss of ultrafiltration. The up-regulation of fibroblast
growth factor 2 (FGF-2) and transforming growth factor-
b (TGF-b) also stimulates interstitial fibrosis of the peri-
toneum [24, 26].
Although each step has been documented in vitro, the
entire hypothesis is yet to be validated in vivo. In order
to test our hypothesis in vivo and to develop a therapeu-
tic approach toward a better dialysis compatibility, we
used a uremic rat model (subtotal nephrectomy), which
subsequently underwent peritoneal dialysis with the con-
ventional glucose-based dialysate, and evaluated the pro-
tective effects of pyridoxamine, a recently developed,
potent inhibitor of AGEs and carbonyl stress, on func-
tional, structural, and molecular biochemical alterations
of the peritoneal membrane.
METHODS
Animals
The protocol followed for the experiments using an-
imals is summarized in Figure 1. Six-week-old male
Sprague-Dawley rats (CLER Japan, Inc., Tokyo, Japan),
weighing 200 ± 3 g, were randomly assigned into the fol-
lowing groups: sham-operated controls (group 1) (N =
6), uremic rats without peritoneal dialysis (group 2) (N =
12), and uremic rats with peritoneal dialysis (N = 24).
Uremic rats with peritoneal dialysis were subdivided into
two groups: a group in which dialysis was performed with
4.25% Dianeal [3.86% glucose 2.5 in mEq/continuous
ambulatory peritoneal dialysis (CAPD) solution] (Baxter
Health care Corp., Round Lake, IL, USA) (group 3) (N =
12) and the second group in which peritoneal dialysis was
performed with pyridoxamine 5 mg (Pridorine) (Bios-
tratum, Inc., Durham, NC, USA) in 4.25% Dianeal 1 L
treatment groups (group 4) (N = 12).
As reported previously, uremic models were gener-
ated after subjecting them to 5/6 nephrectomy [27, 28].
All the rats were maintained on a standard rat labora-
tory diet (CE 2) (CLER Japan, Inc., Tokyo, Japan) that
contained 1.06% calcium, 0.9% phosphate, 21% protein,
and tap water until the evening before they were sacri-
ficed. At the age of 13 weeks, Rat-o-Ports, each with a
13.5 cm catheter (Access Technologies, Norfolk Medical,
Skokie, IL, USA) were surgically implanted into all the
rats that were anesthetized using isoflurane. The Rats-
o-Ports were implanted subcutaneously in the neck, and
1 week after the implantation, peritoneal dialysis with
30 mL of dialysate, which was administered twice a day,
was initiated. This dialysis was continued for 6 weeks [29].
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Prior to the initiation of peritoneal dialysis, four, five, and
two rats died in the groups 2, 3, and 4, respectively. Fi-
nally, we generated sham-operated controls (group 1) (N
= 6), uremic rats without peritoneal dialysis (group 2) (N
= 8), uremic rats with peritoneal dialysis (group 3) (N =
7), and uremic rats, where peritoneal dialysis was carried
out using 5 mg pyridoxamine (group 4) (N = 10).
Tissue sampling
After 6 weeks of peritoneal dialysis, we injected 4.25%
Dianeal from the access port and performed a peri-
toneal equilibration test (60 minutes). Rats were then
sacrificed by overanesthetization. Plasma was separated
from the heparinized blood obtained at the age of
21 weeks. Mesenterium was excised and evaluated by
using light microscopy or immunohistochemistry. We
confirmed the absence of peritonitis by histologic anal-
ysis in peritoneal tissue specimens (e.g., granulocytes
infiltration).
Plasma and peritoneal dialysate analyses
Plasma and peritoneal dialysate concentrations of glu-
cose, creatinine, urea, total cholesterol, and triglyceride
were measured using an autoanalyser (Hitachi Model
736-60) (Hitachi Electronics Co., Ltd., Tokyo, Japan).
Pentosidine measurement by high-performance liquid
chromatography (HPLC)
Pentosidine content in rat peritoneum was assessed by
an HPLC assay in keeping with a previously described
method [30]. Approximately 100 mg of peritoneal tissue
was homogenized with 1.5 mL of chloroform/methanol
(2:1) and subsequently with 1.0 mL of methanol to re-
move lipid. The homogenized tissue was then dried un-
der vacuum and hydrolyzed by 500 lL of 6 N HCl for
16 hours at 110◦C. Acid hydrolysates were dried in vacuo
and reconstituted with 400 lL of 10 mmol/L HCl, filtered
through a 0.5 lm pore filter, and diluted with phosphate-
buffered saline (PBS) with a pH of 7.4. The diluted sam-
ple was injected into an HPLC system and separated on a
C18 reverse-phase column (5 lm, 4.6 × 250 mm) (Waters,
Tokyo, Japan). The effluent was monitored using a fluo-
rescence detector (RF-10A) (Shimadzu, Tokyo, Japan)
and an excitation emission wavelength of 335/385 nm.
Synthetic pentosidine [30] was used to obtain a standard
curve.
Immunohistochemistry
Immunohistochemical study was performed using
formalin-fixed and paraffin-embedded sections. Four
micrometer sections were cut from paraffin blocks,
dewaxed, and dehydrated in graded ethanol. Primary
antibodies used in the present study were anti-TGF-b1
antibody (1:40) (Santa Cruz Biotechnology, Santa Cruz,
CA, USA), anti-von Willebrand factor antibody (1:400)
(Dako, Glostrup, Denmark), anti-VEGF antibody
(1:100) (Santa Cruz Biotechnology), anti-FGF-2 anti-
body (1:400) (Santa Cruz Biotechnology), and anti-AGE
antibody (1:200) (Trans Genic Inc., Kumamoto, Japan).
The sections were deparaffinized in xylene and dehy-
drated through an ethanol series. Endogenous peroxi-
dase activity was inhibited by soaking the sections in 0.3%
H2O2 prepared in methanol for 10 minutes at room tem-
perature. The heat-induced epitope retrieval method was
performed. After washing with PBS, the sections anti-
TGF-b1, von Willebrand factor, FGF-2, and VEGF an-
tibody were heated in a 500 watt microwave oven for
10 minutes at 100◦C in 0.01 mol/L citrate buffer with
a pH of 6.0. The sections were incubated with primary
antibodies for 1 hour at room temperature. Next, the
sections were rinsed and incubated with the secondary
antibody (Nichirei Corp., Tokyo, Japan) for 45 minutes
and were soaked in 0.2% 3, 3-diaminobenzidine tetrahy-
drochloride (DAB), followed by counterstaining with
hematoxylin. The specificity of the immunolabeling was
examined using nonimmune rabbit or goat IgG.
Evaluation of the number of blood vessels
The number of blood vessels was assessed in sections
stained for von Willebrand factor by image analysus soft-
ware (Win ROOF) (Mitani Corp., Tokyo, Japan). All an-
imal subjects were used for the analysis. The average of
the number of capillaries in 20 randomly selected corti-
cal fields was estimated using a ×40 objective. The results
were demonstrated in terms of fold changes as compared
to the control animals of group 1.
Detection of VEGF and FGF-2 expressions
Expressions of VEGF and FGF-2 (mesenterium)
mRNA were analyzed by using semiquantitative reverse
transcriptase-polymerase chain reaction (RT-PCR). The
total RNA was isolated from the mesenterium by us-
ing Isogen (Nippon Gene, Tokyo, Japan). Two micro-
grams of the RNA was reverse transcribed using ran-
dom primer (Life Technologies BRL, Grand Island, NY,
USA) with 200 units of Maloney murine leukemia virus
(MMLV) reverse transcriptase (New England BioLabs,
Inc., Ipswitch, MA, USA), and PCR amplification was
performed as described previously [31]. The oligonu-
cleotides primer sequences were as follows. Primers for
VEGF were 5′-ACT GGA CCC TGG CTT TAC TGC-
3′ and 5′-TTG GTG AGG TTT GAT CCG CAT G-3′;
the full-length amplified fragment is 310 bp long. Primers
for FGF-2 were 5′-CAA GCA GAA GAG AGA GGA
GTT-3′ and 5′-TCA AGC TCT TAG CAG ACA TTG-
3′; the full-length amplified fragment is 276 bp long. The
primers used for rat b-actin were 5′-GTG TGA TGG
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Table 1. Biochemistry and body weight (21 weeks)
Plasma creatinine Plasma urea Plasma glucose Triglyceride Total cholesterol
Groups mg/dL mg/dL mg/dL mg/dL mg/dL Body weight g
1 (N = 6) 0.3 ± 0.0 16.0 ± 2.4 185.5 ± 64.9 141.7 ± 13.5 71.0 ± 13.5 530 ± 37
2 (N = 8) 1.3 ± 0.6a 68.0 ± 35.7a 137.5 ± 31.9 146.6 ± 46.9 117.3 ± 25.6a 416 ± 56a
3 (N = 7) 1.6 ± 0.3a 62.8 ± 13.0a 121.1 ± 36.5 157.1 ± 58.4 143.1 ± 33.9a 435 ± 10a
4 (N = 10) 1.3 ± 0.3a 70.1 ± 23.4a 155.2 ± 20.5 122.5 ± 50.2 125.4 ± 31.8a 419 ± 29a
aP < 0.01 vs. group 1.
TGG GTA TGG GTC AGA AGG ACT-3′ and 5′-ATG
GCA TGA GGG AGC GCG TAA CCC TCA TAG-
3′ and they amplified a 402 bp fragment. The b-actin
served as an internal RNA control to enable compari-
son of RNA levels among different specimens. The spec-
imens were amplified in a DNA Thermal Cycler (Perkin
Elmer Cetus, Norwalk, CT, USA) for suitable cycles of 1
minute at 94◦C, 1 minute at 58◦C for VEGF or FGF-2,
and 1 minute at 60◦C and 1 minute at 72◦C for b-actin.
In the preliminary experiments, RT and PCR amplifica-
tion were performed on various amounts of RNA for
18, 21, 25, 28, 31, 34, and 36 cycles. These experiments
showed that, with 35 cycles of amplification for VEGF
or FGF-2 mRNA and with 16 or 21 cycles of b-actin
mRNA amplification, the differences in the PCR prod-
uct signal were quantitatively related to the input RNA.
The PCR products that were resolved by electrophore-
sis on a 2% agarose gel and stained using ethidium bro-
mide were quantified by measuring the signal intensity
with a quantitation program (NIH image). Messenger
RNA was determined in triplicate and the results were
averaged for each experiment. A total of three indepen-
dent experiments were performed for each experimental
condition. The results were averaged and expressed as
mean ± SD.
Statistical analysis
Results were expressed as means ± SD. All data
were initially subjected to one-way analysis of variance
(ANOVA), followed by multiple comparisons using Dun-
nett test with group 1 as control. Unpaired Student
t test was utilized for two-group comparisons. The corre-
lations between plasma creatinine, dialysate/plasma ratio
(D/P) D/Pcreatinine, D/Purea, D/Pglucose, and the number of
the vessels and pentosidine content were analyzed using
Pearson’s correlation test. In this study, statistical analy-
sis was used with SPSS software (SPSS Inc., Chicago, IL,
USA) to observe the significant difference. P values less
than 0.05 were considered significant.
RESULTS
Functional analysis
The biochemical data and the body weight of the ure-
mic rats with subtotal nephrectomy are shown in Table 1.
Significant increases in the levels of plasma creatinine,
urea, and total cholesterol and a decrease in the body
weight were observed in the uremic rats (groups 2 to 4)
as compared with the nonuremic control rats (group 1).
Among the uremic groups that underwent peritoneal
dialysis and/or pyridoxamine treatment, no significant
differences were observed after statistical analysis. The
plasma levels of glucose and triglycerides were not statis-
tically different across all groups.
Functional parameters of the peritoneal membrane
evaluated at 13 weeks after subtotal nephrectomy showed
that the transport rate of small solutes (i.e., creatinine,
urea) from the plasma (Fig. 2A and B) and absorption
rate of glucose from the dialysate (Fig. 2C) were signif-
icantly higher in the uremic rats (group 2) than in the
control rats (group 1). Significant correlations were ob-
served between the increased permeability for creatinine
(Fig. 3A) or glucose (Fig. 3B) and the degree of renal
failure. These data agree with a recent observation by
Combet et al [9] that chronic uremia by itself modifies
the peripheral membrane and increases the EPSA.
The permeability characteristics of the peripheral
membrane are progressively modified during peritoneal
dialysis. Peritoneal dialysis with a conventional glucose-
based dialysate for 6 weeks significantly increased the
transport rate of small solutes from the plasma (group 3)
(Fig. 2A and B) and absorption rate of glucose from the
dialysate (Fig. 2C).
Pyridoxamine treatment (5 mg/L) for 6 weeks sig-
nificantly decreased the transport rate of small solutes
from the plasma (group 4) (Fig. 2A and B) and the ab-
sorption rate of glucose from the dialysate (Fig. 2C).
Pyridoxamine treatment (1 mg/L) was not sufficiently ef-
ficient to improve the functional alterations of peritoneal
membrane in our study (data not shown). As shown in
Figure 3, pyridoxamine dramatically lowered the slope
of the regression line between the increased permeabil-
ity for small solutes (creatinine and glucose) and the de-
gree of renal failure. Pyridoxamine treatment was very
effective in inhibiting the effect of uremia on membrane
permeability.
Histologic analysis
An increased EPSA is known to be closely related to
enhanced angiogenesis. Therefore, we counted the num-
ber of vessels in the peritoneal tissue after von Willebrand
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Fig. 2. Functional analysis of peritoneal
membrane by peritoneal equilibration test
(PET). The dialysate-to plasma (D/P) ratio of
creatinine (A) and urea (B), and the absorp-
tion of glucose from the dialysate D/D0) (C)
were assessed, during a 60-minute exchange
with 20 mL of 3.85% glucose dialysate, in
control rats (group 1), uremic rats without
peritoneal dialysis (group 2), uremic rats un-
dergoing peritoneal dialysis in the absence of
pyridoxamine (group 3), and uremic rats un-
dergoing peritoneal dialysis in the presence of
5 mg/L pyridoxamine (group 4).
factor staining (Fig. 4A). Uremia by itself caused a 1.87-
fold increase in the vessel number and peritoneal dialysis
treatment markedly augmented the value, resulting in a
5.83-fold increase in the vessel number. This enhanced
angiogenesis was significantly ameliorated by pyridox-
amine treatment and the resultant increase in the vessel
number was 2.68-fold. Significant correlations were ob-
served between the increased permeability for creatinine
(Fig. 4B) or glucose (Fig. 4C) and the number of vessels,
implicating an increased EPSA in the functional deteri-
oration of peritoneal membrane associated with uremia
and peritoneal dialysis treatment.
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Fig. 3. Correlations between the increased permeability for creatinine
(A) or glucose (B) and the degree of renal failure. (•) Group 2 (A)
(N = 8) (r = 0.73, P < 0.05); (B) (N = 8) (r = 0.02, P > 0.1). ()
Group 3 (A) (N = 7) (r = 0.76, P > 0.05); (B) (N = 7) (r = 0.93,
P < 0.01). () Group 4 (A) (N = 10) (r = 0.24, P > 0.1); (B) (N =
10) (r = 0.025, P > 0.1). Chronic uremia increases the permeability
for small solutes, which is further increased by peritoneal dialysis with
conventional glucose-based dialysate. On the other hand, pyridoxamine
treatment was effective in preserving membrane permeability caused
in uremia.
P < 0.01
P < 0.01 P < 0.01
Group 1 Group 2 Group 3 Group 4
*P < 0.01 vs. Group 1
0
1
2
3
4
5
6
7
8
9
N
um
be
r o
f t
he
 v
e
ss
e
ls,
 
vW
F 
st
ai
ni
ng A
*
*
*
D
/D
0 
gl
uc
os
e,
 
60
 m
in
Number of the vessels, vWF staining
0
0.1
0.2
0.3
0.4
0.5
0.6
0 5 10 15
C
D
/P
 c
re
at
in
in
e,
 
60
 m
in
Number of the vessels, vWF staining
0
0.2
0.4
0.6
0.8
1.0
1.2
0 5 10 15
B
Fig. 4. Structural analysis of peritoneal membrane by immunohisto-
chemistry for von Willebrand factor (vWF). (A) Number of the ves-
sels in the mesenterium of rats. Significant correlations exist between
the increased permeability for creatinine (B) (N = 31, r = 0.65, P <
0.001) or glucose (C) (N = 31, r = 0.64, P < 0.001) and the number of
vessels. Chronic uremia increases the number of vessels, which is fur-
ther increased by peritoneal dialysis with conventional glucose-based
dialysate but is decreased by pyridoxamine treatment.
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Fig. 5. Advanced glycation end produce (AGE) content of peritoneal
membrane by high-performance liquid chromatography (HPLC) assay.
(A) Pentosidine content in the mesenterium of rats. (B) A significant
correlation exists between mesenterium pentosidine content and the
degree of renal failure permeability for creatinine. (•) Group 2 (N =
8) (r = 0.98, P < 0.01). () Group 3 (N = 7) (r = 0.82, P < 0.01). ()
Group 4 (N = 10) (r = 0.35, P > 0.1). Chronic uremia increases mesen-
terium pentosidine content, which is further increased by peritoneal
dialysis with conventional glucose-based dialysate but is decreased by
pyridoxamine treatment.
The thickness of the submesothelial connective tissue
in the mesenterium is increased in uremic rats (group 2)
and markedly in peritoneal dialysis rats (group 3) (P <
0.01). Pyridoxamine given in peritoneal dialysis rats re-
duced the thickness of the mesenterium but the difference
was not statistically significant.
Molecular biologic analysis
Pentosidine content increased during uremia (group 2)
(Fig. 5A) and a correlation existed between the tis-
sue pentosidine content and the degree of renal failure
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Fig. 6. Correlations between mesenterium pentosidine content and the
permeability for creatinine or the number of vessels. Mesenterium
pentosidine content correlates with the permeability for creatinine
(A) (N = 31) (r = 0.65, P < 0.001) or the number of vessels (B)
(N = 31) (r = 0.46, P < 0.01).
(Fig. 5B). The formation of pentosidine was further accel-
erated during the peritoneal dialysis treatment (group 3)
(Fig. 5A) and peritoneal dialysis increased the steepness
of the regression line between the pentosidine content
and the degree of renal failure (Fig. 5B). In contrast, inter-
vention by pyridoxamine significantly lowered the tissue
pentosidine content (group 4) (Fig. 5A) and the steep-
ness of the regression line (Fig. 5B). There are significant
correlations between the tissue pentosidine content and
the increased permeability for creatinine (Fig. 6A) or the
number of vessels (Fig. 6B).
Next, we analyzed the gene expressions of VEGF and
FGF-2 in the peritoneal tissues by semiquantitative PCR
to elucidate the role of angiogenic cytokines. The ex-
pressions of VEGF (Fig. 7B) and FGF-2 (Fig. 7C) were
higher in the uremic rats than in the control rats and were
markedly enhanced by peritoneal dialysis treatment. On
the other hand, pyridoxamine decreased both VEGF and
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Fig. 7. Detection of angiogenic cytokine expression. The expressions
of vascular endothelial growth factor (VEGF) or fibroblast growth
factor 2 (FGF-2) mRNAs were analyzed by semiquantitative reverse
transcriptase-polymerase chain reaction (RT-PCR) in the mesenterium
(A). Mean ratio of VEGF or FGF-2 mRNAs over b-actin was calculated
for each experiment. The average of the three experiments is expressed
for VEGF (B) or FGF-2 (C).
FGF-2 expressions to levels similar to that observed in
uremic rats without peritoneal dialysis.
Molecular biologic alterations of peritoneal membrane
were further supported by the immunohistochemistry
of VEGF, FGF-2, von Willebrand factor, AGEs, and
TGF-b1 in the mesenterium tissue sections (Fig. 8). In
the control rats, the stainings indicating the biomark-
ers VEGF, FGF-2, AGEs, and TGF-b1 were virtually
undetectable in the endothelium lining the mesenterial
blood vessels. However, these biomarkers, which were
indicated by stainings, were faintly present in the peri-
toneal membrane of uremic rats and were prominent in
uremic rats that underwent peritoneal dialysis treatment.
On the other hand, only faint stainings were detected in
the capillaries of the mesenterium in rats administered
with pyridoxamine.
DISCUSSION
Our hypothesis is that peritoneal membrane dysfunc-
tion and ultrafiltration failure in long-term peritoneal
dialysis patients are associated with biochemical alter-
ations in the peritoneum, at least in part, due to the re-
active carbonyl compounds overload, originating from
uremic circulation as well as heat-sterilization of glucose
peritoneal dialysis fluid (peritoneal carbonyl stress). In
order to test this hypothesis, we used a uremic rat model
that underwent peritoneal dialysis and evaluated the pro-
tective effects of pyridoxamine, a recently developed, po-
tent inhibitor of AGEs and carbonyl stress, on structural,
functional, and biochemical alterations of the peritoneal
membrane.
Uremic peritoneal membrane was characterized by an
increased functional area of exchange for small solutes
between the blood and the dialysate, vascular prolifer-
ation, increased AGE genesis, and up-regulated expres-
sions of angiogenic cytokines (i.e., VEGF and FGF-2).
The functional, structural, and biochemical alterations
of peritoneal membrane associated with peritoneal dial-
ysis are similar but more severe than those present in
chronic uremia without peritoneal dialysis. Administra-
tion of pyridoxamine in uremic rats with peritoneal dial-
ysis significantly reduced transport rates for small solutes
and density of blood vessels, suggesting its beneficial role
against ultrafiltration failure. This improvement was ac-
companied by a reduction in both AGE accumulation
and angiogenic cytokine expressions.
Thus, peritoneal carbonyl stress resulting from uremic
environments as well as from the peritoneal dialysis pro-
cedure contributes to the vascular proliferation by the
induction of bioactive molecules and an increased func-
tional area of exchange for small solutes, eventually lead-
ing to ultrafiltration failure.
Some strategies to reduce the peritoneal carbonyl
stress have been documented. These include the use of
glucose-free peritoneal dialysis fluids wherein glucose is
replaced with other osmotic agents (e.g., icodextrin and
amino acids) or the use of a multicompartment bag, in
which glucose is maintained at a low pH. There was a
marked decrease in the total RCOs content (e.g., gly-
oxal, methylglyoxal, and 3-deoxyglucosone) as compared
with the conventional heat-sterilized glucose-based peri-
toneal dialysis fluids. Another noteworthy strategy is the
use of compounds with RCO binding properties that
are immobilized on beads or in a cartridge in order
to adsorb RCOs in conventional heat-sterilized glucose
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Fig. 8. Immunohistochemical detections of vascular endothelial growth factor (VEGF), fibroblast growth factor 2 (FGF-2), von Willebrand factor
(vWF), advanced glycation end products (AGEs), and transforming growth factor-b1 (TGF-b1) in the mesenterium. VEGF (A), FGF-2 (B), vWF
(C), AGEs (D), and TGF-b1 (E) stainings were virtually undetectable in the peritoneal membrane of control rats, whereas these biomarkers were
faintly present in uremic rats and were prominent in uremic rats with peritoneal dialysis treatment. On the other hand, only faint stainings were
detected in the capillaries of the mesenterium in rats administered with pyridoxamine (magnification ×200).
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peritoneal dialysis. The addition of polystyrene sulfonyl
hydrazide beads or diaminoguanidine agarose beads
added to the heat-sterilized glucose peritoneal dialy-
sis fluid decreases the levels of glyoxal and methyl-
glyoxal as well as the generation of pentosidine and
Ne-(carboxymethyl) lysine (CML) after incubation [15–
18, 32–34]. Nevertheless, the benefits of a lower RCO
content of peritoneal dialysis fluids might be mitigated
by the changes in the peritoneal fluid RCO content oc-
curring during dwell time [12]. Individual RCOs, such as
glyoxal, methylglyoxal, and 3-deoxyglucosone, fall pro-
gressively in icodextrin effluents or remain undetectable
in amino acid effluents. In contrast, with dwell time, total
RCOs accumulated in uremic serum diffuse within the
peritoneal cavity with a marked increase in the AGE for-
mation potential of the peritoneal dialysis fluid.
An alternative therapeutic strategy might rely on com-
pounds that are known to inhibit AGE formation. This
approach enables us to reduce the peritoneal carbonyl
stress originating not only from peritoneal dialysis flu-
ids but also from uremic circulation. Compounds such as
aminoguanidine and OPB-9195 that contain a hydrazine
nitrogen atom, are able to react with carbonyl groups
and eventually form hydrazone [35–37]. We have demon-
strated that the addition of OPB-9195 or aminoguanidine
to commercial glucose peritoneal dialysis fluids reduced
the generation of pentosidine and CML [37]; this is in
agreement with a previous study carried out by Lamb,
Catell, and Dawney [38] who reported that aminoguani-
dine inhibited the fluorescence intensity on albumin incu-
bated in heat-sterilized glucose peritoneal dialysis fluid.
We further documented a dramatic fall in glyoxal, methyl-
glyoxal, and 3-deoxyglucosone levels within 24 hours of
incubation of peritoneal dialysis fluids with OPB-9195 or
aminoguanidine [37]. These carbonyl-scavenging agents
have further benefits because they block carbonyl stress-
mediated intracellular signaling [39]. However, clinical
trials of aminoguanidine as well as those of OPB-9195 in
diabetic patients have been hampered due to the neuro-
toxicity of these compounds that occurs largely due to the
trapping of pyridoxal [40].
Hudson et al [41–43] have recently identified a new
class of AGE inhibitor, namely, pyridoxamine. The in-
hibitory mechanism of AGEs by pyridoxamine remains
elusive. Pyridoxamine was first described as a post-
amadori inhibitor of AGE formation [41]. It is also a
potent nucleophile and may trap dicarbonyl interme-
diates during AGE formation [43]. Subsequently, Ono-
rato et al [44] demonstrated that pyridoxamine inhibits
the modification of lysine residues in RNase and in a
low-density lipoprotein during metal catalyzed oxida-
tion reactions and the formation of AGEs (CML and
CEL) as well as advanced lipoxidation end products
(ALEs) (malondialdehyde-lysine and hydroxynonenal-
lysine) [44]. Unlike aminoguanidine and OPB-9195, pyri-
doxamine does not trap pyridoxal. Its preclinical efficacy
has been proven in animal models having type 1 and
2 diabetic nephropathy [45–48]. A phase 2 clinical trial
for diabetic patients has been completed in the United
States. Thus, pyridoxamine is safer than aminoguanidine
and OPB-9195.
Pyridoxamine treatment significantly decreased the
transport rate of small solutes from the plasma and the
absorption rate of glucose from the dialysate. This func-
tional improvement of peritoneal membrane was con-
comitant with amelioration of enhanced angiogenesis
as well as expressions of angiogenic cytokines induced
by both uremia and peritoneal dialysis. Intervention by
pyridoxamine significantly lowered the tissue pentosi-
dine content. Therefore, pyridoxamine may be benefi-
cial in the protection of uremic peritoneal membrane on
peritoneal dialysis by improvement of functional, struc-
tural, and molecular biochemical alterations of peritoneal
membrane.
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